Skip to main content

Table 5 Frequencies of features by rheumatic disease type (N = 45)

From: Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

 

RA (n = 22)

Lupus (n = 5)

PMR (n = 4)

PsA (n = 4)

AS (n = 2)

Limited SSc (n = 2)

Sarcoidosis (n = 2)

SS (n = 2)

DM (n = 1)

UCTD (n = 1)

Flare (n = 13)

10

0

0

1

1

0

0

1

0

0

irAE (n = 20)

9

3

2

1

2

0

1

1

0

1

AEs (Grade 1–2) (n = 19)

11

3

1

0

2

0

0

2

0

0

SAEs (Grade 3 +) (n = 8)

4

0

1

1

0

0

1

0

0

1

ICI therapy held (n = 16)

6

3

1

1

2

0

1

1

0

1

Required systemic steroids (n = 21)

12

1

2

1

2

0

1

1

0

1

  1. RA, Rheumatoid arthritis; PMR, Polymyalgia Rheumatica; PsA, Psoriatic Arthritis; AS, Ankylosing Spondylitis; SSc, Scleroderma; SS, Sjogren's Syndrome; DM, dermatomyositis; UCTD, undifferentiated connective tissue disease; irAE, immune related adverse event; AE, adverse event; SAE, serious adverse event; ICI, immune checkpoint inhibitor
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us